Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-2 in metastatic melanoma and kidney cancer
NCT01355562Phase 2Withdrawn
- Sponsor
- Loma Linda University
- Start
- Mar 2011
- Primary completion
- Feb 2012
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of aldesleukin in melanoma and renal cell carcinoma (RCC), sponsored by Loma Linda University. Primary endpoint: Objective Response Rate at 9 weeks. Planned start Mar 2011; status: withdrawn.
02
Drugs
aldesleukin
03
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01355562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01355562.